Albemarle CapEx decreased by 36.5% to $98.68M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 46.0%, from $182.62M to $98.68M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -11.3% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $217.23M | $255.82M | $300.93M | $231.70M | $270.91M | $313.33M | $445.71M | $415.61M | $503.69M | $545.90M | $689.35M | $583.04M | $451.55M | $303.13M | $342.81M | $182.62M | $119.63M | $132.16M | $155.39M | $98.68M |
| QoQ Change | — | +17.8% | +17.6% | -23.0% | +16.9% | +15.7% | +42.3% | -6.8% | +21.2% | +8.4% | +26.3% | -15.4% | -22.6% | -32.9% | +13.1% | -46.7% | -34.5% | +10.5% | +17.6% | -36.5% |
| YoY Change | — | — | — | — | +24.7% | +22.5% | +48.1% | +79.4% | +85.9% | +74.2% | +54.7% | +40.3% | -10.4% | -44.5% | -50.3% | -68.7% | -73.5% | -56.4% | -54.7% | -46.0% |